**Clinical Pre-screening Protocol for Ovarian Cancer** This study is about finding out if certain cancer drugs can help patients with ovarian cancer. *Ovarian cancer* is a type of cancer that starts in the ovaries, which are part of the female reproductive system. The study uses pieces of the patient's tumor tissue, called FFPE, from when the cancer first appeared or from when it spread. These tissue samples help researchers see if the patient might benefit from new cancer drugs in the future. The study will also look at past treatments to see how well they worked and if the new method called DRP® can predict future treatment success. **Key Points:** - The study is for patients whose ovarian cancer is *platinum-resistant*, meaning it came back within 6 months after platinum-based chemotherapy. - Participants should have used one or fewer treatments after becoming platinum-resistant or ineligible. - Tissue samples (FFPE) are needed for the study. *Note: The study is not for those whose cancer didn't respond to the last platinum treatment.*